Last reviewed · How we verify
Purinostat Mesylate for Injection
Purinostat Mesylate for Injection is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and changes in gene expression.
Purinostat Mesylate for Injection is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and changes in gene expression. Used for Relapsed or refractory peripheral T-cell lymphoma.
At a glance
| Generic name | Purinostat Mesylate for Injection |
|---|---|
| Sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This mechanism of action is thought to contribute to the induction of apoptosis and inhibition of cell proliferation in cancer cells. Histone deacetylase inhibitors like Purinostat Mesylate for Injection have been shown to have anti-tumor activity in various preclinical models.
Approved indications
- Relapsed or refractory peripheral T-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Anorexia
- Weight loss
- Hypokalemia
Key clinical trials
- A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma (PHASE2)
- Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (PHASE2)
- Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant (PHASE1)
- A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma (PHASE3)
- A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: